Will witness good credit growth this year, says Bandhan Bank-March 2024-www.financetom.com

Will witness good credit growth this year, says Bandhan Bank

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Will witness good credit growth this year, says Bandhan Bank

Jun 8, 2018 1:49 AM

Bank will witness good credit growth this year, said Chandra Shekhar Ghosh, MD and CEO, Bandhan Bank.

Talking about the business, he said that the rural cash flow is expected to improve.

Macquarie has initiated coverage on the stock with an overweight rating and a target of Rs 560.

Previous page： Blue Origin New Glenn rocket deploys Mars satellites in company's first NASA mission Next page： Animal health firm ImmuCell Q3 sales fall 8%, hurt by previous production interruptions

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Blue Origin New Glenn rocket deploys Mars satellites in company's first NASA mission

Nov 13, 2025

CAPE CANAVERAL, Florida (Reuters) -The Blue Origin space venture of billionaire Jeff Bezos launched its giant New Glenn rocket from Florida on Thursday on its debut flight for paying customers, carrying two satellites on their way to Mars in the company's first NASA-scale science mission. The powerful two-stage rocket, standing 32 stories tall, blasted off from Cape Canaveral Space Force...

Animal health firm ImmuCell Q3 sales fall 8%, hurt by previous production interruptions

Nov 13, 2025

Overview * ImmuCell Q3 2025 product sales decreased by 8% yr/yr to $5.5 mln * Company reported a net loss of $140,000 for Q3 2025 * Gross margin improved to 43% in Q3 2025 from 26% in Q3 2024 Outlook * Company continues to collect market feedback on Re-Tain through 2026 * ImmuCell ( ICCC ) has sufficient inventory to...

BioAtla Q3 net loss widens to $15.8 mln

Nov 13, 2025

Overview * BioAtla ( BCAB ) Q3 net loss widens to $15.8 mln, driven by absence of collaboration revenue * R&D expenses decreased due to program prioritization and workforce reduction * Company in advanced stages to finalize strategic transaction by year-end Outlook * BioAtla ( BCAB ) expects to complete a strategic partnership by year end Result Drivers * Research...

Alternative investment manager Caliber Q3 revenue misses estimates, hurt by deconsolidations

Nov 13, 2025

Overview * Caliber Q3 revenue drops to $3.6 mln from $11.3 mln due to deconsolidations * Net loss for Q3 at $4.4 mln, driven by investment impairment charges * Adjusted EBITDA for Q3 misses estimates, reporting a loss of $0.7 mln Outlook * Company did not provide specific financial guidance for future periods Result Drivers * EQUITY RAISE - Caliber...